# The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients

Study · id `cardio:ct-nct02251847` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02251847](<https://clinicaltrials.gov/study/NCT02251847>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02251847

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

## Technical summary

Registry record NCT02251847. Randomized; double masking; primary purpose treatment. Start 2014-07 (registry gives no type); primary completion 2015-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT02251847, source copy `cardio:ctgov-nct02251847-2014-09-29`, retrieved 2026-10-31)
- Start date: 2014-07 (registry gives no type) (ClinicalTrials.gov record NCT02251847, source copy `cardio:ctgov-nct02251847-2014-09-29`, retrieved 2026-10-31)
- Primary completion: 2015-07 (anticipated) (ClinicalTrials.gov record NCT02251847, source copy `cardio:ctgov-nct02251847-2014-09-29`, retrieved 2026-10-31)
- Completion: Not reported
- Countries: South Korea (ClinicalTrials.gov record NCT02251847, source copy `cardio:ctgov-nct02251847-2014-09-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02251847-2014-09-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients
- Condition: Hypercholesterolemia
- Intervention (Drug): Rosuvastatin/Ezetimibe
- Lead sponsor: IlDong Pharmaceutical Co Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: IlDong Pharmaceutical Co Ltd (`cardio:org-ildong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 34476c0b7d2cb15b15b59a55a3af6442d599554da945c6f2760c2de71b0246c5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
